COSCIENS Biopharma Inc. - Common Stock CSCI 深 沪
等待开盘 08-19 09:30:00 美东时间
2.89
+0.040
+1.40%
华盛通- 最 高2.91
- 今 开2.89
- 成交量 7096股
- 最 低 2.7001
- 昨 收 2.85
- 总市值 909.48万
- 52周最高 5.86
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 1.96
- 委 比 -98.02%
- 总股本 314.70万
- 历史最高 35500.00
- 量 比 0.73
- 振 幅 7.36%
- 历史最低 1.96
- 每 手 1
- 风险率 0.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
COSCIENS Biopharma Inc. has reported its Q2 2025 financial results, showcasing a 17% revenue increase, 19% gross profit rise, and 28% reduction in operating expenses compared to Q2 2024. The company's Board of Directors has approved a plan to voluntarily delist from Nasdaq while maintaining its TSX listing to reduce costs and focus on core operations. The restructuring included a 27% workforce reduction, part of a broader strategy to enhance effi...
08-14 21:20
Perrigo Announces Agreement to Divest Dermacosmetics Business for up to €327 Million
Transaction Advances Company's 'Three-S' Plan to Streamline its Portfolio and Strengthen Focus on its 'High-Grow' Brands Total Consideration of Up to €327 Million, Consisting of €300 Million...
07-14 20:30
Perrigo To Scale And Optimize Global Category-Led, Market Activation Growth Model
Roberto Khoury, EVP & President Consumer Self-Care International (CSCI), Appointed to New Position of EVP & Chief Commercial Officer to Lead Global Market ActivationTriona Schmelter, EVP & President Consumer
07-02 04:34
Perrigo Announces Strategic Organizational Update to Drive Sustainable Growth and Performance
Company to Scale and Optimize Global Category-Led, Market Activation Growth Model Roberto Khoury, EVP & President Consumer Self-Care International (CSCI), Appointed to New Position of EVP & ...
07-02 04:30
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
COSCIENS Biopharma Inc. held its virtual annual general and special meeting (AGSM) where shareholders voted on key matters. Five directors—Peter H. Puccetti, Anthony J. Giovinazzo, Ulrich Kosciessa, Robert A. Seager, and David Spear—were elected with high approval rates (88.89% to 88.92%). Ronald W. Miller was elected with 68.75% approval. Deloitte LLP was appointed as the auditor, and the Amended and Restated Shareholder Rights Plan was approved...
06-30 22:33
COSCIENS Biopharma reconstitutes board
COSCIENS Biopharma (NASDAQ:CSCI) announced that Peter Puccetti has been appointed Board Chair; key board committees have also been restructured. Source: Press release More on COSCIENS Biopharma Inc. F...
05-31 05:24
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
COSCIENS Biopharma Inc. announces the consensual reconstitution of its board of directors to better create value for shareholders. The Reconstituted Board now includes six directors: Anthony J. Giovinazzo, Ulrich Kosciessa, Ronald W. Miller, Peter H. Puccetti, Robert A. Seager, and David Spear. The board aims to strengthen corporate governance and review the company's prospects. Goodwood Inc. agrees to support the re-election of these directors, ...
05-30 21:00
COSCIENS Biopharma Receives Director Nominations from Goodwood
COSCIENS Biopharma ( ($TSE:CSCI) ) has provided an update. COSCIENS Biopharma I...
05-26 19:07
COSCIENS Biopharma Completes Merger with Ceapro and Restructures Governance
COSCIENS Biopharma ( ($TSE:CSCI) ) has shared an update. COSCIENS Biopharma Inc...
05-21 05:47
